Literature DB >> 2212539

The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics.

T Nagate1, K Numata, K Hanada, I Kondo.   

Abstract

The antibacterial activities of antiulcer agents and antibiotics against Campylobacter pylori were studied. The MIC90 values of three kinds of antibiotics--macrolides, beta-lactams, and metronidazole--were 0.05-0.78, 0.39-1.56, and 12.5 micrograms/ml, respectively. They were more active than antiulcer agents such as H2-blockers and cetraxate with MIC90 values of greater than or equal to 1,600 and greater than 1,600 micrograms/ml, respectively. Especially, clarithromycin, a new derivative of erythromycin, showed an MIC90 of 0.05 microgram/ml. However, the other antiulcer agents such as sofalcone and tripotassium dicitrate bismuthate (TDB) also had MIC90 values of 50 and 6.25 micrograms/ml, respectively. Clarithromycin, sofalcone, and TDB showed bactericidal activity against C. pylori CLO2. The bactericidal actions of these drugs could be observed under electron microscopy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2212539     DOI: 10.1097/00004836-199001001-00023

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.

Authors:  J M Meyer; S Ryu; S L Pendland; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 2.  Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.

Authors:  A Burette; Y Glupczynski
Journal:  Infection       Date:  1995       Impact factor: 3.553

3.  Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.

Authors:  Hajime Isomoto; Hisashi Furusu; Ken Ohnita; Chun-Yang Wen; Kenichiro Inoue; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 4.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

5.  Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes.

Authors:  R C Goldman; D Zakula; R Flamm; J Beyer; J Capobianco
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.

Authors:  L E Gustavson; J F Kaiser; A L Edmonds; C S Locke; M L DeBartolo; D W Schneck
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

Authors:  G J Malanoski; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

8.  Helicobacter pylori in duodenal ulcer patients with idiopathic gastric acid hypersecretion.

Authors:  M J Collen; R M Strong
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

Review 9.  Flavonoids with gastroprotective activity.

Authors:  Kelly Samara de Lira Mota; Guilherme Eduardo Nunes Dias; Meri Emili Ferreira Pinto; Anderson Luiz-Ferreira; Alba Regina Monteiro Souza-Brito; Clélia Akiko Hiruma-Lima; José Maria Barbosa-Filho; Leônia Maria Batista
Journal:  Molecules       Date:  2009-03-03       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.